Novonesis AS 

$70.29
216
+$1.68+2.45%Thursday 19:40

Statistics

Day High
65.33
Day Low
65
52W High
73.07
52W Low
52.1
Volume
500
Avg. Volume
478
Mkt Cap
0
P/E Ratio
43.84
Dividend Yield
1.46%
Dividend
1.02

Upcoming

Dividends

1.46%Dividend Yield
Aug 2026
$0.37
Mar 2026
$0.66
Aug 2025
$0.35
Apr 2025
$0.62
Sep 2024
$0.30
10Y Growth
4.08%
5Y Growth
4.01%
3Y Growth
-10.9%
1Y Growth
5.56%

Earnings

Feb 11Expected
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Q3 2026
Next
2.73
3.53
4.34
5.15
Expected EPS
4.287040182105
Actual EPS
N/A

Financials

13.97%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
4.79BRevenue
668.54MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVZMF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap167.52B
Pfizer is a global pharmaceutical company that competes with Novonesis AS in the development and marketing of medications and vaccines for various diseases, including those in areas where Novonesis may operate.
Merck
MRK
Mkt Cap361.73B
Merck & Co., Inc. is a leading healthcare company that develops innovative pharmaceuticals and vaccines, directly competing with Novonesis AS in several therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap664.95B
Johnson & Johnson is a diversified healthcare giant that competes with Novonesis AS through its pharmaceutical division, developing drugs that may overlap with Novonesis' product portfolio.
GSK
GSK
Mkt Cap100.88B
GlaxoSmithKline is a global healthcare company that competes with Novonesis AS in the pharmaceutical and healthcare market, particularly in the development of vaccines and medications.
Novartis
NVS
Mkt Cap307B
Novartis is a multinational pharmaceutical company that competes with Novonesis AS in researching, developing, manufacturing, and marketing a wide range of healthcare products.
Abbvie
ABBV
Mkt Cap514.92B
AbbVie is a biopharmaceutical company that competes with Novonesis AS in the discovery, development, and commercialization of new medicines and therapies.
Bristol-Myers Squibb
BMY
Mkt Cap127.02B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Novonesis AS in the development of prescription pharmaceuticals in several therapeutic areas.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a healthcare company that competes with Novonesis AS in the pharmaceutical and diagnostics industries, focusing on oncology, immunology, and infectious diseases.
Sanofi
SNY
Mkt Cap112.71B
Sanofi is a global healthcare leader that competes with Novonesis AS in the development and marketing of therapeutic solutions in areas such as rare diseases, multiple sclerosis, and oncology.
Astrazeneca
AZN
Mkt Cap289.14B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Novonesis AS in the discovery, development, and commercialization of prescription medicines, particularly in the oncology sector.

About

Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends internationally, serving markets in Denmark, the rest of Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America. Novozymes' diverse portfolio includes protein solutions for the food and beverage sector, alongside a comprehensive suite of cleaning and hygiene offerings for industrial, medical, and household applications, such as drain openers, septic tank treatments, ware washing, and professional laundry. In agriculture, they supply solutions for various crops like corn, cotton, soybeans, and wheat, focusing on bioyield and biocontrol, in addition to animal health and nutrition products and aquaculture systems for warm water species. The company actively supports sustainable industrial processes with contributions to bioenergy (including ethanol, biodiesel, renewable diesel, biogas, and wastewater treatment), biorefining (encompassing fiber modification, bleach boosting, deposit control, starch modification, carbon capture), and applications for textiles and leather. Their extensive range of enzyme solutions, such as lipases, proteases, oxidoreductases, and carbohydrases, are crucial for processes like corn and wheat separation, liquefaction, and saccharification. Furthermore, Novozymes addresses human health with solutions targeting brain, oral, protective, immune, and gastrointestinal well-being, while also engaging in areas like biocatalysis, cell culture, and diagnostics.
Show More
CEO
Ester Baiget
Employees
11098
Country
Denmark
ISIN
DK0060336014
WKN
000A1JP9Y

Listings

0 Comments

Share your thoughts

FAQs

What is Novonesis AS stock price today?▼
The current price of NVZMF is $70.29 USD — it has increased by +2.45% in the past 24 hours. Watch Novonesis AS stock price performance more closely on the chart.
What is Novonesis AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Novonesis AS stocks are traded under the ticker NVZMF.
Is Novonesis AS stock price growing?▼
NVZMF stock has risen by +8.14% compared to the previous week, the month change is a +8.14% rise, over the last year Novonesis AS has showed a +11.59% increase.
When is the next Novonesis AS earnings date?▼
Novonesis AS is going to release the next earnings report on February 11, 2027.
What were Novonesis AS earnings last quarter?▼
NVZMF earnings for the last quarter are 0.61 USD per share, whereas the estimation was 0.75 USD resulting in a -18.11% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Novonesis AS revenue for the last year?▼
Novonesis AS revenue for the last year amounts to 4.79B USD.
What is Novonesis AS net income for the last year?▼
NVZMF net income for the last year is 668.54M USD.
Does Novonesis AS pay dividends?▼
Yes, NVZMF dividends are paid semi-annual. The last dividend per share was 0.37 . As of today, Dividend Yield (FWD)% is 1.46%.
How many employees does Novonesis AS have?▼
As of November 9, 2026, the company has 11,098 employees.
In which sector is Novonesis AS located?▼
Novonesis AS operates in the Materials sector.
When did Novonesis AS complete a stock split?▼
The last stock split for Novonesis AS was on November 28, 2011 with a ratio of 5:1.
Where is Novonesis AS headquartered?▼
Novonesis AS is headquartered in Lyngby, Denmark.